Motley Fool11d agoneutral
Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call TranscriptGrowth portfolio now drives 60% of revenue as Eliquis surges 21%.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
39last 24h
1801last 7d
299● bullish (7d)
170● bearish (7d)
205publishers
Stocktwits12d agoneutral
MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August TradingDecisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.
Barchart12d agoneutral
The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up TodayBristol-Myers stock extends gains on reports of a potential merger with AstraZeneca. But caution is warranted in chasing the momentum in BMY shares today.
GuruFocus.com12d agobearish
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger TalksInvestors questioned whether combining AstraZeneca with Bristol Myers would strengthen growth enough to justify the financial and regulatory risks.
Moby12d agoneutral
AstraZeneca Eyes a Pharma Megamerger Nobody Asked ForThe UK drugmaker is reportedly talking to Bristol Myers Squibb about a nearly $400 billion tie-up, but investors are struggling to diagnose the logic.
24/7 Wall St.12d agoneutral
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.
Bloomberg12d agoneutralVIDEO
AstraZeneca Investors See Little Logic in Bristol Tie-UpAstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss.
PA Media: Money12d agoneutral
Stocks mixed as AstraZeneca merger talk dents FTSE 100The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
Pharmaceutical Technology12d agobearish
AstraZeneca shares slump after $400bn BMS merger rumoursOne of the largest global pharma companies would be created if a deal were to materialise.
Investing.com12d agoneutral
Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?BMY surged roughly 6% in premarket trading on the news before fading; the stock is now trading near flat. The asymmetric price reaction captures the market's immediate verdict: AZN shareholders see a value-destructive deal, while BMY holders see a potential premium exit.
MT Newswires12d agoneutral
European Stocks Close Mostly Higher in Monday Trading; AstraZeneca Reportedly in Merger Talks With Bristol MyersEuropean stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa
Zacks12d agoneutral
4 Biotech Stocks Likely to Outpace Q2 Earnings EstimatesMedical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Investopedia12d agobullish
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZenecaBristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
Investor's Business Daily12d agoneutral
AstraZeneca Stock Nosedives On Mega-Merger RumorAstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.
Proactive12d agoneutral
Medicus Pharma CMO to lead Antev's Teverelix clinical programmeMedicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidiary Antev Limited, consolidating leadership of the Teverelix clinical programme ahead of regulatory, late-stage development and partnering work. Dr Faisal Mehmud will become Antev’s chief...
Quartz12d agoneutral
AstraZeneca, Bristol Myers Squibb exploring merger talksA combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times
GuruFocus.com12d agoneutral
AstraZeneca Weighs a Deal Its CEO Said It Didn't NeedCombined group would rank fourth by market value
Investopedia12d agoneutral
5 Things to Know Before the Stock Market Opens on MondayNews of the day for Monday, August 3
TheStreet12d agoneutral
Morgan Stanley uncovers major Bristol Myers stock signalsBristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report and kept its rating exactly where it was. (The source of much of this article is a Morgan Stanley report shared with me.) Morgan Stanley sees the stock falling to $40, well ...
Proactive12d agoneutral
Analysts baffled by AstraZeneca's interest in Bristol Myers SquibbAstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled to explain why Britain's largest drugmaker would want to buy Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP). Jefferies described the reported talks...
The Wall Street Journal12d agoneutral
Health Care Roundup: Market TalkFind insight on AstraZeneca , Bristol Myers Squibb, Hartalega and more in the latest Market Talks covering health care.
